Table 3.
Summary of clinical trials of first-line ICIs combined with anti-angiogenic therapy or dual ICI combination therapy for advanced NSCLC
| Study | Patient | Arm | ORR, % | DOR, median, months | PFS |
OS |
Grade ≥ 3 TRAEs, % | ||
|---|---|---|---|---|---|---|---|---|---|
| Median, months | HR (95% CI) | Median, months | HR (95% CI) | ||||||
| ICIs combined with antiangiogenic therapy | |||||||||
| IMpower150 | Advanced non-squamous NSCLC | Atezolizumab + bevacizumab + chemotherapy vs. Bevacizumab + chemotherapy | 63.5 vs. 48.0 | 9.0 vs. 5.7 | 8.3 vs. 6.8 | 0.62 (0.52–0.74) | 19.2 vs. 14.7 | 0.78 (0.64–0.96) | 58.5 vs. 50 |
| Dual ICI combination therapy | |||||||||
| CheckMate 227 | Advanced NSCLC | Nivolumab + ipilimumab vs. chemotherapy | 33.1 vs. 27.8 | 19.6 vs. 5.8 | 5.1 vs. 5.5 | 0.79 (0.69–0.91) | 17.1 vs. 13.9 | 0.73 (0.64–0.84) | 32.8 vs. 36 |
| CheckMate 9LA | Advanced NSCLC | nivolumab + ipilimumab+ chemotherapy vs. chemotherapy | 38.2 vs. 24.9 | 11.3 vs. 5.6 | 6.7 vs. 5.0 | 0.68 (0.57–0.82) | 15.6 vs. 10.9 | 0.66 (0.55–0.80) | 47 vs. 38 |
| POSEIDON | Advanced NSCLC | Tremelimumab + durvalumab + chemotherapy vs. chemotherapy | 38.8 vs. 24.4 | 9.5 vs. 5.1 | 6.2 vs. 4.8 | 0.72 (0.60–0.86) | 14.0 vs. 11.7 | 0.77 (0.65–0.92) | 51.8 vs. 44.4 |
ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; TPS, tumor proportion score; ORR, objective response rate; DOR, duration of response; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; TRAE, treatment-related adverse event.